NEW YORK, August 4, 2022 — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that its Board of Directors has approved a ratio of 1-for-15 reverse share split of its common shares. As a result of […]
Read MoreYou are leaving MindMed and will be automatically redirected to ${url} in a moment.
Change your mind?
Return to Mindmed
